Literature DB >> 31409883

Glucose disturbances, cognitive deficits and white matter abnormalities in first-episode drug-naive schizophrenia.

Xiangyang Zhang1,2,3, Mi Yang4,5, Xiangdong Du6, Wei Liao5, Dachun Chen7, Fengmei Fan7, Meihong Xiu7, Qiufang Jia6, Yuping Ning8, Xingbing Huang8, Fengchun Wu8, Jair C Soares9, Bo Cao9, Li Wang10, Huafu Chen11.   

Abstract

Disturbance of glucose metabolism may be implicated in cognitive deficits of schizophrenia in its early phases. Many studies have reported the important role of widespread disruption of white matter (WM) connectivity in pathogenesis, cognitive deficit and psychopathology of schizophrenia. However, no study has investigated their inter-relationships in drug-naive first episode (DNFE) patients with schizophrenia. Glucose metabolism parameters including fasting glucose, insulin and homeostasis model of assessment-insulin resistance (HOMA-IR) index, cognitive performance on the MATRICS Consensus Cognitive Battery (MCCB) and the voxel-wised WM fractional anisotropy (FA) values were examined using DTI in 39 DNFE schizophrenia and 31 control subjects. The Positive and Negative Syndrome Scale was utilized for clinical symptoms. The patients showed significantly greater fasting plasma levels of glucose and insulin and HOMA-IR, and poorer cognitive scores, together with widespread reduced FA values in five brain areas, including left and right corpus callosum, superior longitudinal fasciculus, posterior thalamic radiation, and corona radiata (all p < 0.05). Association analysis showed that glucose level was positively associated with Digital Sequence Test and Continuous Performance Test, but negatively with FA values in posterior thalamic radiation and left corpus callosum in patients (all p < 0.05). Furthermore, multiple regression analysis revealed that the interactions of glucose × FA in left corpus callosum, longitudinal fasciculus and corona radiata were independent contributors to the Brief Visuospatial Memory Test (BVMT) of MCCB, while the interaction of glucose × FA in left corpus callosum, or in longitudinal fasciculus was associated with MCCB mazes and Trail Making A Test, respectively. Therefore, abnormal glucose metabolism, cognitive impairment and widespread disruption of WM structure occur in an early course of schizophrenia onset. An interaction between glucose metabolism abnormality and the WM dysconnectivity may lead to cognitive impairment.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31409883     DOI: 10.1038/s41380-019-0478-1

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  68 in total

Review 1.  Atypical antipsychotic drugs, schizophrenia, and metabolic syndrome in non-Euro-American societies.

Authors:  Rami Bou Khalil
Journal:  Clin Neuropharmacol       Date:  2012 May-Jun       Impact factor: 1.592

2.  Impaired glucose tolerance in first-episode drug-naïve patients with schizophrenia.

Authors:  L M Spelman; P I Walsh; N Sharifi; P Collins; J H Thakore
Journal:  Diabet Med       Date:  2007-03-22       Impact factor: 4.359

Review 3.  The prevention of diabetes and cardiovascular disease in people with schizophrenia.

Authors:  R I G Holt
Journal:  Acta Psychiatr Scand       Date:  2015-05-15       Impact factor: 6.392

Review 4.  Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders--a systematic review and meta-analysis.

Authors:  Alex J Mitchell; Davy Vancampfort; Kim Sweers; Ruud van Winkel; Weiping Yu; Marc De Hert
Journal:  Schizophr Bull       Date:  2011-12-29       Impact factor: 9.306

Review 5.  The prevalence and predictors of type two diabetes mellitus in people with schizophrenia: a systematic review and comparative meta-analysis.

Authors:  B Stubbs; D Vancampfort; M De Hert; A J Mitchell
Journal:  Acta Psychiatr Scand       Date:  2015-05-05       Impact factor: 6.392

6.  A meta-analysis of cardio-metabolic abnormalities in drug naïve, first-episode and multi-episode patients with schizophrenia versus general population controls.

Authors:  Davy Vancampfort; Martien Wampers; Alex J Mitchell; Christoph U Correll; Amber De Herdt; Michel Probst; Marc De Hert
Journal:  World Psychiatry       Date:  2013-10       Impact factor: 49.548

Review 7.  Metabolic complications of schizophrenia and antipsychotic medications--an updated review.

Authors:  J Yogaratnam; N Biswas; R Vadivel; R Jacob
Journal:  East Asian Arch Psychiatry       Date:  2013-03

8.  Metabolic profile of antipsychotic-naive individuals with non-affective psychosis.

Authors:  Emilio Fernandez-Egea; Miguel Bernardo; Thomas Donner; Ignacio Conget; Eduard Parellada; Azucena Justicia; Enric Esmatjes; Clemente Garcia-Rizo; Brian Kirkpatrick
Journal:  Br J Psychiatry       Date:  2009-05       Impact factor: 9.319

Review 9.  First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis.

Authors:  M Smith; D Hopkins; R C Peveler; R I G Holt; M Woodward; K Ismail
Journal:  Br J Psychiatry       Date:  2008-06       Impact factor: 9.319

10.  Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia.

Authors:  Martina C M Ryan; Patrick Collins; Jogin H Thakore
Journal:  Am J Psychiatry       Date:  2003-02       Impact factor: 18.112

View more
  10 in total

1.  Metabolic disturbances, hemoglobin A1c, and social cognition impairment in Schizophrenia spectrum disorders.

Authors:  Sunny X Tang; Lindsay D Oliver; Katrin Hänsel; Pamela DeRosse; Majnu John; Ammar Khairullah; James M Gold; Robert W Buchanan; Aristotle Voineskos; Anil K Malhotra
Journal:  Transl Psychiatry       Date:  2022-06-06       Impact factor: 7.989

2.  Interrelationships Between BDNF, Superoxide Dismutase, and Cognitive Impairment in Drug-Naive First-Episode Patients With Schizophrenia.

Authors:  Mei Hong Xiu; Zezhi Li; Da Chun Chen; Song Chen; Maile E Curbo; Hanjing Emily Wu; Yong Sheng Tong; Shu Ping Tan; Xiang Yang Zhang
Journal:  Schizophr Bull       Date:  2020-12-01       Impact factor: 9.306

Review 3.  Repurposing of Anti-Diabetic Agents as a New Opportunity to Alleviate Cognitive Impairment in Neurodegenerative and Neuropsychiatric Disorders.

Authors:  Qian Chen; Ting Cao; NaNa Li; Cuirong Zeng; Shuangyang Zhang; Xiangxin Wu; Bikui Zhang; Hualin Cai
Journal:  Front Pharmacol       Date:  2021-05-24       Impact factor: 5.810

Review 4.  Oxidative-Antioxidant Imbalance and Impaired Glucose Metabolism in Schizophrenia.

Authors:  Amira Bryll; Justyna Skrzypek; Wirginia Krzyściak; Maja Szelągowska; Natalia Śmierciak; Tamas Kozicz; Tadeusz Popiela
Journal:  Biomolecules       Date:  2020-03-02

5.  Cognitive deficits and white matter abnormalities in never-treated first-episode schizophrenia.

Authors:  Mi Yang; Shan Gao; Xiangyang Zhang
Journal:  Transl Psychiatry       Date:  2020-11-02       Impact factor: 6.222

6.  Advances in schizophrenia research: glycobiology, white matter abnormalities, and their interactions.

Authors:  Julio Licinio; Ma-Li Wong
Journal:  Mol Psychiatry       Date:  2020-12-03       Impact factor: 15.992

7.  A bottom-up model of functional outcome in schizophrenia.

Authors:  Hongge Luo; Yanli Zhao; Fengmei Fan; Hongzhen Fan; Yunhui Wang; Wei Qu; Zhiren Wang; Yunlong Tan; Xiujun Zhang; Shuping Tan
Journal:  Sci Rep       Date:  2021-04-07       Impact factor: 4.379

8.  Shi-Zhen-An-Shen Decoction, a Herbal Medicine That Reverses Cuprizone-Induced Demyelination and Behavioral Deficits in Mice Independent of the Neuregulin-1 Pathway.

Authors:  Chao Ma; Yan Wu; Xinyao Liu; Yi He; Yuan Jia; Pei Chen; Dongqing Yin; Yanzhe Ning; Guoqiang Xing; Zuoli Sun; Hongxiao Jia
Journal:  Neural Plast       Date:  2021-02-25       Impact factor: 3.599

Review 9.  Crosstalk between Schizophrenia and Metabolic Syndrome: The Role of Oxytocinergic Dysfunction.

Authors:  Kah Kheng Goh; Cynthia Yi-An Chen; Tzu-Hua Wu; Chun-Hsin Chen; Mong-Liang Lu
Journal:  Int J Mol Sci       Date:  2022-06-25       Impact factor: 6.208

10.  Assessment of Appetite-Regulating Hormones Provides Further Evidence of Altered Adipoinsular Axis in Early Psychosis.

Authors:  Michał Lis; Bartłomiej Stańczykiewicz; Lilla Pawlik-Sobecka; Agnieszka Samochowiec; Artur Reginia; Błażej Misiak
Journal:  Front Psychiatry       Date:  2020-05-29       Impact factor: 4.157

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.